in-PharmaTechnologist.com presents its periodic round-up of personnel changes in pharmaceutical manufacturing and development.
Aesica, a supplier of active pharmaceutical ingredients and formulated products to the pharmaceutical industry has appointed Anthony Higham to the post of operations director. In this role Mr Higham will take responsibility for operations at Aesica's three manufacturing sites in the UK.
Mr Higham has more than 20 years experience in the pharmaceutical industry, most recently as divisional technical head within global manufacturing and supply at GlaxoSmithKline.
Joseph Stowell has been appointed to the US Pharmacopeia Expert Committee for Monograph Development: Ophthalmology, Oncology, and Dermatology.
Mr Stowell works at the Chao Center for Industrial Pharmacy & Contract Manufacturing as its quality assurance director and is also an adjunct assistant professor in Purdue University's School of Pharmacy and Pharmaceutical Sciences.
John Kolman has been appointed to the post of senior director of research and development at US-based contract services company BioReliance.
Mr Kolman was previously principal scientist on the HLA single antigen initiative and lung cancer biomarker programmes at Invitrogen and has also been a researcher at the Salk Institute.
Biovail, Canada's biggest publicly traded pharmaceutical company has appointed William Wells to the post of CEO.
Mr Wells had been working as chief financial officer at Loblaw Companies and has also been a director at Biovail since 2005. The majority of Mr Wells' career has been spent in the food industry and he has previously held a senior position at McDonalds.
BaroFold, a bio-therapeutics company utilising its process technologies to develop and commercialize improved protein therapeutics, has appointed Jon Saxe to its board of directors.
Mr Saxe is currently a director of numerous biotechnology and pharmaceutical companies and has held positions in the industry for over 30 years.
Swiss-based Addex Pharmaceuticals has appointed Laurent Massuyeau as head of business development and elected Dr Ray Hill to its board of directors.
Mr Massuyeau was previously executive director of European commercial operations at Idenix Pharmaceuticals. Dr Hill is leaving his post as executive director, licensing and external research, Europe for Merck Sharp & Dohme Research Laboratories, a subsidiary of Merck & Co to take the post at Addex.
Resolvyx Pharmaceuticals has appointed Timothy Barberich and George Milne to its board of directors. Resolvyx is focused on developing drugs based on resolvins, which are naturally-occurring, small molecule lipid mediators that actively resolve inflammation.
Mr Barberich and Mr Milne have both held a range of executive positions within the pharmaceutical industry and Resolvyx, which has just received $25m in venture capital, feels it will benefit greatly from their experience.